Abbott Laboratories' Xience V stent prevented more heart attacks with fewer complications after two years than Boston Scientific's rival Taxus Express, a study has found. Patients with the Abbott stent were 30 percent less likely to have a heart attack or other major stent failure than those given Boston Scientific's Taxus Express, Abbott-sponsored researchers found. Blood-clot formation, a serious complication, occurred 64 percent less often in the Xience group, Bloomberg reports. Article